How This Works
Bremelanotide is a synthetic analog of α-melanocyte-stimulating hormone that acts as a non-selective melanocortin receptor agonist, predominantly targeting MC3R and MC4R[3]. In the central nervous system, MC4R activation enhances dopamine release in key brain reward and arousal regions including the nucleus accumbens and medial preoptic area, which increases sexual motivation and desire[3]. Unlike PDE5 inhibitors, bremelanotide does not directly affect the nitric oxide pathway; in men, its erectogenic effect is secondary to this central mechanism stimulating nitric oxide production in penile tissue[3]. Peripheral MC1R agonism accounts for observations such as transient blood pressure elevation and skin hyperpigmentation (tanning)[3][5].
Intranasal (IN) Research Summary
Bremelanotide was initially developed and studied via the intranasal route before the formulation was selected for FDA approval. The following bullets summarize reported findings from peer-reviewed literature. This section reports study data only and does not constitute a protocol or recommendation.
- Route studied: Intranasal (IN) delivery via metered-dose nasal spray was the primary route in early-phase clinical trials of PT-141 for both male erectile dysfunction and female sexual arousal disorder (reported in studies)[14][15].
- Male ED trials (human, RCT): A double-blind, placebo-controlled, at-home study in men with erectile dysfunction evaluated intranasal bremelanotide at prepared amounts of 7 mg and 20 mg via nasal spray. The study reported statistically significant improvements in erectile function versus placebo (reported in studies)[14].
- Female arousal trials (human, RCT): Intranasal bremelanotide was studied in premenopausal women with female sexual arousal disorder. Prepared amounts of 20 mg IN were reported, with significant increases in subjective arousal and desire versus placebo (reported in studies)[15].
- Bioavailability comparison: The route demonstrated approximately 100% bioavailability, whereas intranasal bioavailability was substantially lower and more variable across subjects. This pharmacokinetic limitation contributed to the selection of measurement for the approved Vyleesi product (reported in studies)[3][10].
- Blood pressure concerns: Intranasal preparation was associated with more pronounced transient increases in blood pressure compared with delivery, which was a factor in the route switch during clinical development (reported in studies)[10][16].
- Delivery form and device: Studies used aqueous solution delivered via a metered-dose nasal spray pump. Specific device specifications (delivered volume per actuation) were not consistently reported across publications[14][15].
- Nausea incidence: Nausea was the most commonly reported adverse event with intranasal bremelanotide, occurring at higher rates with higher prepared amounts. This observation was also dose-limiting in some subjects (reported in studies)[3][16].
- PK variability: Inter-subject variability in Cmax and AUC was notably higher with the intranasal route than with measurement, attributed to differences in nasal mucosal absorption, mucus clearance, and technique (reported in studies)[3][17].
- Key limitation: The intranasal route for bremelanotide was ultimately not pursued for regulatory approval due to the combination of lower and more variable bioavailability, higher incidence of blood pressure elevation, and less predictable pharmacokinetics compared with the route (reported in studies)[10][17].
Nasal Spray Device Output & Conversion Math
Important: Nasal spray pumps vary in delivered volume per actuation depending on manufacturer, model, and priming state. The mcg delivered per spray is entirely dependent on the specific device used. Always verify the delivered volume per actuation from the manufacturer’s specifications or by direct gravimetric measurement. This section provides a parameterized measurement framework only and does not suggest any particular preparation regimen.
Parameterized Framework
Inputs:
concentration_mcg_per_mL— peptide concentration after reconstitution (or convert: mg/mL × 1000 = mcg/mL)pump_output_mL_per_actuation— delivered volume per spray (from manufacturer specs or direct measurement)
Output:
amount_mcg_per_actuation=concentration_mcg_per_mL×pump_output_mL_per_actuation
Optional Volume Mapping (U-100 Convention)
If “units” are used as a volume shorthand (where 100 units = 1.0 mL on a U-100 scale):
pump_output_mL_per_actuation=units_per_actuation/ 100amount_mcg_per_actuation=concentration_mcg_per_mL× (units_per_actuation/ 100)
Nasal Actuation Calculation Table (Placeholders)
| Concentration (mcg/mL) | Pump Output (mL/actuation) | Amount per Actuation (mcg) | Actuations per mL | Total Actuations in Reconstituted Volume |
|---|---|---|---|---|
| [A] | [B] | [A] × [B] | 1 / [B] | [Recon. vol. mL] × (1 / [B]) |
| [C] | [D] | [C] × [D] | 1 / [D] | [Recon. vol. mL] × (1 / [D]) |
Worked Examples (Placeholders Only)
Example 1 (mL-based pump): If concentration = 3333 mcg/mL (i.e., 10 mg reconstituted in 3.0 mL) and pump output = 0.10 mL/actuation, then amount per actuation = 3333 × 0.10 = 333.3 mcg/spray. Actuations per mL = 1 / 0.10 = 10. Total actuations in 3.0 mL = 30.
Example 2 (units-based): If concentration = 3333 mcg/mL and pump delivers 13 units/actuation, then pump output = 13 / 100 = 0.13 mL. Amount per actuation = 3333 × 0.13 = 433.3 mcg/spray. Actuations per mL = 1 / 0.13 ≈ 7.7. Total actuations in 3.0 mL ≈ 23.
These examples use the PT-141 10 mg / 3.0 mL reconstitution concentration for illustrative math only. They do not represent recommended prepared amounts. Device-specific calibration is essential.
Important Note
This content is for educational purposes only and is not medical advice.